Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors
- Bianca AW Hoeben†1Email author,
- Maud HW Starmans†2, 3,
- Ralph TH Leijenaar2,
- Ludwig J Dubois2,
- Albert J van der Kogel1,
- Johannes HAM Kaanders1,
- Paul C Boutros3, 4, 5,
- Philippe Lambin2 and
- Johan Bussink1
© Hoeben et al.; licensee BioMed Central Ltd. 2014
Received: 23 November 2013
Accepted: 18 February 2014
Published: 26 February 2014
Quantification of molecular cell processes is important for prognostication and treatment individualization of head and neck cancer (HNC). However, individual tumor comparison can show discord in upregulation similarities when analyzing multiple biological mechanisms. Elaborate tumor characterization, integrating multiple pathways reflecting intrinsic and microenvironmental properties, may be beneficial to group most uniform tumors for treatment modification schemes. The goal of this study was to systematically analyze if immunohistochemical (IHC) assessment of molecular markers, involved in treatment resistance, and 18F-FDG PET parameters could accurately distinguish separate HNC tumors.
Several imaging parameters and texture features for 18F-FDG small-animal PET and immunohistochemical markers related to metabolism, hypoxia, proliferation and tumor blood perfusion were assessed within groups of BALB/c nu/nu mice xenografted with 14 human HNC models. Classification methods were used to predict tumor line based on sets of parameters.
We found that 18F-FDG PET could not differentiate between the tumor lines. On the contrary, combined IHC parameters could accurately allocate individual tumors to the correct model. From 9 analyzed IHC parameters, a cluster of 6 random parameters already classified 70.3% correctly. Combining all PET/IHC characteristics resulted in the highest tumor line classification accuracy (81.0%; cross validation 82.0%), which was just 2.2% higher (p = 5.2×10-32) than the performance of the IHC parameter/feature based model.
With a select set of IHC markers representing cellular processes of metabolism, proliferation, hypoxia and perfusion, one can reliably distinguish between HNC tumor lines. Addition of 18F-FDG PET improves classification accuracy of IHC to a significant yet minor degree. These results may form a basis for development of tumor characterization models for treatment allocation purposes.
KeywordsHead and neck cancer Tumor characterization 18F-FDG PET Immunohistochemistry
In the past decades, radiotherapy has become a preferred treatment modality for advanced head and neck cancer (HNC). To increase treatment outcome, radiotherapy is given in accelerated schedules and is often combined with chemotherapy and/or biologically targeted therapies . HNC require a more extensive characterization than is currently performed, in order to enhance clinical prognosis estimation, to enable therapy response prediction and to give direction to tailored therapy selection from the different therapy modalities available to patients. Molecular and biological tumor characteristics, such as proliferation rate and extent of hypoxia which are known radiation-resistance mechanisms in HNC , can be analyzed [e.g. with immunohistochemistry (IHC)] next to the histopathological and anatomical tumor traits that are commonly used for therapy allocation . In studies, tumors are often assessed regarding only one or a few specified biologic markers, such as hypoxia, proliferation or a certain biologic target, and based on this limited information assigned to a particular phenotype . The next step to predict intrinsic tumor behavior, such as metastatic potential or probable therapy-response, would be to combine a group of biomarkers involved in multiple cellular pathways . However, the optimal combination and amount of markers for various predictive assays in radiation oncology is still unknown . Furthermore, even if tumors are categorized to a similar phenotype based on one characteristic, they can display discordances regarding other cellular mechanisms. For instance, equally hypoxic HNC tumors can show discrepant proliferation rates [7, 8]. This may even apply for different regions within one tumor . The tumor microenvironment plays an important role in the activation of cellular mechanisms . Characterization of HNC, incorporating several aspects of phenotype markers representing multiple pathways influenced by intrinsic and extrinsic factors, might help pave the way for accurate distinction of individual tumors from other tumors of the same origin. A set of adequately selected parameters based on biological processes may deliver accurate all-round tumor classification for grouping of uniform tumors for treatment allocation, prediction of treatment response or distinction of patient groups with a different prognosis.
Development of such a set of parameters would best be performed in a patient cohort, taking multiple biopsies per tumor, since a single biopsy will not represent marker expression of entire tumors . However, taking additional biopsies for study-purposes is often impossible to achieve. We established 14 HNC xenograft models originating from human head and neck carcinomas, with stability across several passages [12–14]. Nevertheless, biological marker expression within one tumor model displays variation after transplantation of xenograft tumors in different animals, under the influence of external and microenvironmental factors. Using these models, we can evaluate and characterize heterogeneous head and neck tumors as it were of multiple biopsies from 14 different patients. Establishment of a direction to the appropriate size of a classification parameter-set in such tumor models may be extrapolated to the clinical situation.
The availability of non-invasive functional imaging modalities broadens the range of possibilities for quantification of HNC biological traits [15, 16]. Positron emission tomography (PET) with the glucose analogue 2-[18F] fluoro-2-deoxy-D-glucose (18F-FDG) is a powerful molecular imaging method exploiting increased metabolic activity of cancer cells . Research is still focused on identifying the multifactorial molecular mechanisms underlying the cancer cells’ altered glucose metabolism . Nonetheless, qualitative 18F-FDG PET is increasingly implemented before, during and after radiotherapy for HNC . Quantification of differences in 18F-FDG tumor uptake may supplement IHC tumor characterization. In this study, we systematically analyzed an array of tumor parameters, to investigate if parameters derived from the imaging modalities 18F-FDG PET and IHC, singularly or in combination, could reliably distinguish different human HNC xenograft models from one another. The IHC markers were selected based on their association with 18F-FDG accumulation and relationship, on a molecular basis, with tumor cell metabolism, and radiotherapy-resistance mechanisms proliferation and hypoxia .
Xenograft tumor models
Ninety-eight female BALB/c nu/nu mice (Central Animal Laboratory Radboud University Medical Center) were xenografted with MEC82 (mucoepidermoid carcinoma), SCCNij or FaDu (squamous cell carcinomas) head and neck primary tumors. All lines but FaDu were derived from patient biopsies obtained in clinical studies from the Radboud University Medical Center conducted between 1996 and 2006 [21–23]. Patients gave written informed consent after approval from the Medical Ethics Committee of the Radboud University Medical Center. All research was conducted in compliance with the Helsinki Declaration and in accordance with Dutch law. Additionally, we created a xenograft model from the FaDu cell line [24, 25]. SCCNij model-numbers were: 3, 59, 68, 86, 153, 154, 167, 172, 185, 196, 202 and 240. The origin of the tumor lines is described in Additional file 1: Table S1. Two-mm3 tumor pieces were implanted subcutaneously in the right flank in 6-8 weeks old mice. Experiments started at an average tumor diameter of 6-8 mm. Ninety-two animals were scanned per protocol; 5 mice per tumor model were used for IHC. Animals were kept in a specific-pathogen-free unit and protocols and institutional guidelines for the proper humane care and use of animals in research were followed. The Animal Welfare Committee of the Radboud University Medical Center approved all experiments.
Small-animal PET imaging and biodistribution
Mice were fasted for 6 hours and were subsequently anesthetized using isoflurane/compressed air before 18F-FDG injection until the end of the experiment. Before and during scans, body temperature was kept within normal range using heated pads and heating lamps . At 45 minutes before imaging, mice were injected intravenously (i.v.) through a tail vein catheter with 0.2 mL/10.2 ± 0.8 MBq 18F-fluoro-2-deoxyglucose (18F-FDG; Department of Nuclear Medicine and PET research, VU University Medical Center, Amsterdam, the Netherlands) followed by 0.1 mL saline to propel 18F-FDG residue from the catheter. Specific activity was > 1 GBq/μmol and radiochemical purity was always > 97% (end of synthesis). Syringes were measured in a dose calibrator before and after injection. Before imaging, bladders were largely emptied by gentle external pressure. Animals were imaged in pairs using an Inveon small-animal PET scanner (Siemens Preclinical Solutions, Knoxville, TN). Tumors were positioned in the center of the field of view. A 15-minute emission scan was acquired followed by a 400-second transmission scan, using the built-in 57Co source (energy window 120-125 keV) for attenuation correction. For assessment of tumor micro-environmental characteristics, mice were injected intra-peritoneally (i.p.) with 80 mg/kg hypoxia-marker pimonidazole hydrochloride (PIMO; 1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride; Hypoxyprobe-1, NPI Inc., Belmont, MA) at 60 minutes before sacrifice and with 50 mg/kg S-phase marker bromodeoxyuridine (BrdU; Sigma, Zwijndrecht, The Netherlands) just before imaging. The perfusion marker Hoechst 33342 (15 mg/kg, Sigma) was injected i.v. 1 minute prior to sacrificing the animals through cervical dislocation.
Tumors and normal tissues were harvested, weighed, and counted in a gamma well counter (1480 Wallac Wizard 3”, PerkinElmer Life Sciences, Boston, MA). The tumors were cut; one half of the tumor was immediately snap-frozen in liquid nitrogen for IHC. Radioactivity uptake in the other half of the tumor and in normal tissues was calculated as percentage of the injected dose per gram of tissue (%ID/g) (Additional file 1: Figure S1). For radioactive decay correction, injection standards were counted simultaneously.
PET image analysis
List mode data were acquired using the default energy and coincidence timing. Data were reconstructed using 3-dimensional ordered subset expectation maximization (OSEM3D, 2 iterations) followed by maximum a posteriori (MAP, 18 iterations, β = 0.05) reconstruction optimized for uniform resolution (Siemens Inveon Acquisition Workplace, version 1.5, Siemens Preclinical Solutions) . Transaxial pixel size was 0.43 mm, plane separation 0.8 mm, and the image matrix 256×256×159 . PET images were analyzed using Siemens Inveon Research Workplace software. Quantification of tracer uptake in volumes of interest (VOIs) drawn around tumor and hind leg muscles on the attenuation corrected images was obtained by calculating the maximum (SUVmax) and mean standardized uptake values (SUVmean). SUV was calculated as a ratio of voxel radioactivity concentration and injected activity (both decay-corrected towards start of scan) divided by body weight. SUVmean for tumors was taken from a PET tumor VOI created using automatic delineation with a fixed 40% SUVmax threshold [29, 30]. Uptake was further quantified as the ratio of mean tumor to mean muscle uptake (T/M).
Frozen tumors were sectioned using a cryostat microtome. Consecutive central 5 μm thick tumor sections were mounted on poly-L-lysine coated slides and stored at -80°C until staining. Slides were scanned for vessel perfusion based on the fluorescent Hoechst 33342 signal before staining for carbonic anhydrase-9 [CA9; primary antibody (PA) biotinylated rabbit anti-CA9 (Novus Biologicals, Littleton, CO)], BrdU [PA sheep anti-BrdU (GeneTex Inc., San Antonio, TX)], PIMO [PA rabbit anti-pimonidazole (J Raleigh, University of North Carolina)], monocarboxylate transporter-4 [MCT4; PA rabbit anti-MCT4 antibody (Santa Cruz Biotechnology, Santa Cruz, CA)], glucose transporter-1 [GLUT1; PA rabbit anti-glut1 (Neomarkers Inc, Fremont, CA)], epidermal growth factor receptor [EGFR; PA goat anti-EGFR sc-03 antibody (Santa Cruz)], phosphorylated protein kinase B [pAKT; PA rabbit anti-pAKT (Santa Cruz)], and blood vessels [PA 9 F1 (rat monoclonal against mouse endothelium, Radboud University Medical Center)]. Specific staining protocols are described in the Additional file 1.
IHC image acquisition and analysis
Tumor sections were analyzed using a digital image analysis system as described previously . After scanning stained whole tissue sections, gray scale images (pixel size 2.59×2.59 μm, dynamic range 4095 grey values) were obtained and subsequently converted into binary images. Thresholds for segmentation of the fluorescent signals were interactively set above the background staining for each IHC image. Binary images were used to calculate fractions of tumor area positive for CA9, EGFR, MCT4, pAKT, GLUT1 and PIMO relative to the total viable tumor area. BrdU labeling index (LI) was determined as the number of positively stained nuclei relative to the total number of nuclei in the tumor area. Vascular density (VD; number of vascular structures per mm2) and perfused vessel fraction (PF) were established. These were the “IHC parameters” analyzed for combined classification accuracy. Areas of necrosis, determined using Hematoxylin and Eosin (HE) stained consecutive tumor sections, were excluded from analysis.
Global texture analysis
Where P defines the first order histogram and P(i) the fraction of voxels with intensity level i. N ι is the number of discrete intensity levels. Developing global texture feature values was possible for most IHC markers, but not when a particular staining followed a thin ribbon-like pattern throughout tumor sections, which was the case for PF and vessels.
All analyses and plotting were performed in R statistical environment (v2.15.2) unless stated otherwise. The packages e1071 (v1.6), lattice (v0.20-13), latticeExtra (v0.6-24), hexbin (v1.26.0) and cluster (v1.14.3) were used for data processing and graphical representation.
Intra- versus inter-tumor line variability
A variance component analysis for all PET and IHC parameters was performed. For each parameter a linear mixed-effects model was fit with tumor line as random effect with the nlme package (v3.1-106). This produces the variance within (intra) a tumor line, the variance between (inter) tumor lines and the total (intra + inter) variance. The ratio intra/inter was calculated and used as a measure of intra-tumor line heterogeneity, as done previously .
Tumor line prediction
To assess whether (combinations of) PET and IHC parameters could distinguish tumor lines we created Random Forest models based on these parameters to predict tumor lines. A Random Forest is an ensemble classifier generated by growing a ‘forest’ of decision trees, where each tree is trained with a different bootstrap subset of tumors and parameters. Approximately a third of the samples are omitted from each tree, creating out-of-bag (OOB) data that is subsequently used to measure classifier performance . For each model a Random Forest consisting of 20,000 trees (with the default number of variables randomly sampled at each split) was built using the randomForest package (v4.6-7). Performance of these predictors was assessed with the OOB error estimate and via cross validation. For cross validation the data were randomly split in training (75% of samples) and test (25% of samples) data. A Random Forest was built in the training set and evaluated in the test set as measured by the percentage of samples correctly classified. This was repeated 1000 times. Cross validation training and test sets were the same for all evaluated models, which allowed for a direct comparison between models. These analyses focused on the 72 tumors with full IHC profiling. For a few samples in this subgroup PET data (4 tumors), MCT4 data (5 tumors) and BrdU data (3 tumors) were not assessable, and median imputation was applied to fill in these missing data (e1071 package v1.6). Accuracy distributions between models were compared by a paired t-test.
Small-animal 18F-FDG PET imaging and IHC
Tumor classification using PET parameters
Intra-tumor line heterogeneity: PET and IHC parameters and features
Within line variance
18 F-FDG PET SUV max
18 F-FDG PET SUV mean
18 F-FDG PET T/M
18 F-FDG PET
Random Forest classifier performance
Accuracy overall model
Accuracy cross validation test set (mean ± SD)
19.0% ± 8.0%
23.1% ± 8.8%
74.9% ± 10.9%
79.8% ± 10.2%
PET + IHC
76.4% ± 11.0%
82.0% ± 10.6%
Tumor classification using PET parameters and PET features
For further analysis of the discriminatory ability of PET, global texture features derived from the individual PET images were added to the model. Although addition of the PET texture features entropy and skewness resulted in a slightly better classification accuracy (26.7%, cross validation accuracy: 23.1% ± 8.8%), these combined parameters still could not differentiate between tumor lines. The intra-tumor line heterogeneities of the PET features were in the same range as those of the PET parameters (Table 1).
Tumor classification using IHC parameters
To investigate whether the combination of IHC parameters could distinguish tumor lines, a Random Forest was built to predict the tumor line from the IHC data. Classification performance of the Random Forest was high (accuracy 76.9% as calculated from the OOB error estimate). This was confirmed in cross validation analysis, where in the test sets 74.9% ± 10.9% of the samples were classified correctly. Since each tree in Random Forest is trained on a bootstrap subset of the parameters, these can be used to estimate the importance of a parameter by calculating the decrease in classification accuracy when the parameter is omitted from a model (Figure 2E). Parameters with smaller intra-tumor line heterogeneity had a bigger effect on accuracy; these were in effect the endogenous markers. Next, we explored the influence of number of IHC parameters on classification accuracy. All possible combinations for 1 up to 8 IHC parameters were used to build a Random Forest. Classification accuracy increased significantly with the number of combined IHC parameters up to 7, and a random combination of 6 parameters already showed a classification accuracy of 70.3% ± 11.4% (Figure 2F).
Tumor classification using IHC features and IHC parameters
IHC global texture features were analyzed combined with IHC parameters. IHC texture features provided more information on marker distribution profiles and complemented IHC quantification values. Intra-line heterogeneity for each IHC feature is given in Table 1 and was higher for exogenous markers than endogenous markers similar to their associated IHC parameters, except for GLUT1; GLUT1 features showed greater heterogeneity than the IHC staining fraction.
Combination of PET and IHC parameters
PET and IHC parameters combined with PET and IHC texture features
All texture features were added to the IHC and PET parameters to investigate whether this would further improve tumor line characterization. A Random Forest was built with these data, which resulted in an accuracy of 81.0%. In cross validation analysis, 82.0% ± 10.6% of the samples were classified correctly. The Random Forest for all data combined resulted in the highest classification accuracy.
The goal of the study was to investigate if parameters derived from 18F-FDG PET imaging and IHC, singularly or in combination, could reliably distinguish different human HNC xenograft models from one another. Eventually, this could give direction to classification methods for clustering of tumors that are most alike regarding multiple characteristics in clinical studies, e.g. for treatment prediction and prognostication purposes or for individualized treatment selection.
IHC markers were selected for relevance in metabolic cell processes and known therapy resistance mechanisms , as well as for (in)direct links to 18F-FDG tumor uptake in the literature [34–38]. Using a systematic analysis method, the presented results show that a finite set of IHC staining parameters, quantifying several relevant molecular cell processes, can accurately allocate a specific tumor to the appropriate tumor line within a cluster of 14 HNC lines. Adding more staining markers increases accuracy, but at a certain point this effect levels off. A specifying accuracy of at least 70% can be achieved with a random set of 6 of these IHC markers.
18F-FDG PET could not differentiate between the HNC lines in this study. Furthermore, quantification parameters (SUV, T/M) and selected 18F-FDG PET texture features did not provide additional value to classification accuracy by IHC alone. It may be unlikely that 18F-FDG PET derived parameters can reliably categorize combined differences in biological characteristics between head and neck tumors. Absolute SUVs were relatively low in this study and were in line with other preclinical HNC studies [39, 40], but lower than the typical SUVs that are detected in clinical HNC . This is inherent to the mouse model used for PET imaging in this study. Although differences were seen between HNC lines, most of the observed variance could be attributed to intra-tumor line differences.
Uptake of 18F-FDG has been assessed for correlation with several biological markers in tumors, such as GLUT1, glycolysis- and hypoxia-related markers [34, 35, 42], proliferation [36, 42, 43], EGFR  and AKT , with conflicting results. Overall, 18F-FDG uptake in malignancies reflects multifactorial mechanisms of increased metabolic activity and glucose utilization, performed by glucose transporters and enzymes in the glycolytic pathway, which in turn are regulated through different signaling pathways triggered by endogenous and exogenous stimulators. Aims to attribute 18F-FDG uptake to expression of one specific protein or therapy resistance mechanism are therefore debatable.
Quantitative texture feature analysis has been introduced in radiodiagnostic imaging as a means to characterize and classify tumors using their signal intensity distribution [44, 45], and studies described the use of texture features as potential prognostic or predictive tools [46, 47]. Textural feature analysis can be applied in numerous imaging modalities where lesion configuration plays a discriminating role for stratification , e.g. contact dermoscopy images  or microscopy images [50, 51]. For this study we focused on a limited set of global features that would give relevant insight in signal distribution next to quantification parameters such as IHC staining fraction or PET SUV, including entropy and skewness for IHC and PET images, with the additional feature “mean” (pixel grey value) for IHC images. IHC texture features combined with IHC parameters conveyed optimal characterization accuracy. However, addition of 21 feature values improved the classification accuracy of the combined 9 IHC parameters (which was already 74.9%) by only 4.9%.
Limitation of the study is the use of relatively small xenograft tumors as opposed to multiple biopsies from larger HN tumors. However, this setup provides the possibility to study multiple parameters in entire tumor sections, which is difficult to achieve on a large scale in a patient setting. In clinical studies, sampling errors by extraction of a single biopsy forms a general pitfall when assessing biological markers with a heterogeneous tumor distribution. At least 4-5 central core biopsies are needed to minimize effects of IHC staining heterogeneity within tumor sections [11, 52]. In entire tumors, an even greater spatial heterogeneity in IHC characteristics is likely to occur. Iakovlev et al. demonstrated that, for CA9 quantification in multiple cervical tumor biopsies per patient, the highest variation was inter-tumor, followed by intra-tumor and intra-tumor section variation. The greatest reduction in assessment-error could be achieved by increasing the number of biopsies spaced well apart rather than increasing the number of stained sections per biopsy .
We analyzed multiple tumors per xenograft model, which have the same genetic background and are grown to a similar size under similar circumstances in mice from the same strain. Even these tumors, that may represent a basic approach to multiple biopsies from heterogeneous tumors in different patients, exhibited variable characteristics during growth, affected by microenvironmental and external factors [53, 54]. Intra-tumor line variation for the administered exogenous markers was overall larger than for endogenous markers. Tumor uptake of exogenous markers is influenced by dosage and administration, circulation and body clearance properties, tumor vascular density and perfusion, diffusion, binding and washout kinetics et cetera. In the clinical situation, external and microenvironmental influences may result in even larger intra-tumor and inter-tumor variation of molecular marker expression in HNC.
Results from the study can be extrapolated to other tumor types in the sense that, when the aim is to allocate or adapt individually tailored treatment, a selection of parameters provides the potential for precise tumor characterization and stratification. Depending on the treatment options at hand, individual tumor profiles or grouping of most uniform tumors can be established with the help of a distinct panel of IHC markers. This precludes analyzing an extensive number of classification parameters.
Care should be taken that the number of chosen characterizing parameters is not too small either. In this study, we found relatively low accuracies when less than 6 IHC parameters were combined for classification. Instead of administering exogenous IHC markers, molecular PET tracers with a more defined imaging spectrum than 18F-FDG, such as tracers for hypoxia or proliferation rate , can potentially complement IHC analyses by visualizing the entire tumor for presence of certain tumor mechanisms relevant for treatment.
In this study, we used a systematic analysis to demonstrate that features of different quantifying methods characterize head and neck tumor lines effectively and complement each other. Multiple IHC and 18F-FDG PET parameters and texture features categorized individual tumors as adequate as possible. However, a select set of IHC marker parameters representing tumor metabolism, proliferation, hypoxia and blood perfusion could already allocate individual tumors to the appropriate HNC line, in an array of 14 HNC lines, with high reliability. Selected IHC texture features complemented IHC parameters for optimal characterization accuracy. 18F-FDG PET parameters and texture features were of minor additional value to the classification accuracy of IHC parameters alone. 18F-FDG as a marker may be too multifactorial influenced to distinguish microenvironmental or molecular differences between HNC lines.
Epidermal growth factor receptor
Hematoxylin and eosin
Head and neck cancer
Maximum a posteriori
3-dimensional ordered subset expectation maximization
Phosphorylated protein kinase B
Positron emission tomography
Pimonidazole (1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride)
Squamous cell carcinoma
Standardized uptake value
Volume of interest.
We thank the central animal research facility staff, of whom especially Bianca Lemmers-Van de Weem and Kitty Lemmens-Hermans for technical assistance, and Peter Laverman, Gerben Franssen, Maarten Blok, Wenny Peeters, Hans Peters, Hanneke Stegeman, Marlous Wennemers, Monique Nijkamp, Jasper Lok (Radboud University Medical Center) and Natasja Lieuwes (MAASTRO) for their contribution to the collection of data. We acknowledge financial support from CTMM (Airforce), EU 7th framework program (METOXIA, ARTFORCE), EU IMI program (QuIC-ConCePT) and NIH-QIN (Radiomics of NSCLC U01 CA143062). This study was conducted with the support of the Ontario Institute for Cancer Research to PCB through funding provided by the Government of Ontario.
- Argiris A, Karamouzis MV, Raben D, Ferris RL: Head and neck cancer. Lancet. 2008, 371: 1695-1709. 10.1016/S0140-6736(08)60728-X.View ArticlePubMedGoogle Scholar
- Bussink J, van der Kogel AJ, Kaanders JH: Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008, 9: 288-296. 10.1016/S1470-2045(08)70073-1.View ArticlePubMedGoogle Scholar
- Begg AC, Stewart FA, Vens C: Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011, 11: 239-253. 10.1038/nrc3007.View ArticlePubMedGoogle Scholar
- Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002, 62: 7350-7356.PubMedGoogle Scholar
- Takes RP, Rinaldo A, Rodrigo JP, Devaney KO, Fagan JJ, Ferlito A: Can biomarkers play a role in the decision about treatment of the clinically negative neck in patients with head and neck cancer?. Head Neck. 2008, 30: 525-538. 10.1002/hed.20759.View ArticlePubMedGoogle Scholar
- Lambin P, van Stiphout RG, Starmans MH, Rios-Velazquez E, Nalbantov G, Aerts HJ, Roelofs E, van Elmpt W, Boutros PC, Granone P, Valentini V, Begg AC, De Ruysscher D, Dekker A: Predicting outcomes in radiation oncology–multifactorial decision support systems. Nat Rev Clin Oncol. 2013, 10: 27-40.View ArticlePubMedGoogle Scholar
- Nyflot MJ, Harari PM, Yip S, Perlman SB, Jeraj R: Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. Radiother Oncol. 2012, 105: 36-40. 10.1016/j.radonc.2012.09.012.View ArticlePubMedPubMed CentralGoogle Scholar
- Wijffels KI, Marres HA, Peters JP, Rijken PF, van der Kogel AJ, Kaanders JH: Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas. Oral Oncol. 2008, 44: 335-344. 10.1016/j.oraloncology.2007.04.004.View ArticlePubMedGoogle Scholar
- Hoogsteen IJ, Marres HA, Wijffels KI, Rijken PF, Peters JP, van den Hoogen FJ, Oosterwijk E, van der Kogel AJ, Kaanders JH: Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res. 2005, 11: 97-106.PubMedGoogle Scholar
- Stegeman H, Kaanders JH, Wheeler DL, van der Kogel AJ, Verheijen MM, Waaijer SJ, Iida M, Grenman R, Span PN, Bussink J: Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer. 2012, 12: 463-10.1186/1471-2407-12-463.View ArticlePubMedPubMed CentralGoogle Scholar
- Iakovlev VV, Pintilie M, Morrison A, Fyles AW, Hill RP, Hedley DW: Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest. 2007, 87: 1206-1217. 10.1038/labinvest.3700680.View ArticlePubMedGoogle Scholar
- Bussink J, Kaanders JH, Rijken PF, Martindale CA, van der Kogel AJ: Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts. Br J Cancer. 1998, 77: 57-64. 10.1038/bjc.1998.9.View ArticlePubMedPubMed CentralGoogle Scholar
- Wijffels KI, Kaanders JH, Marres HA, Bussink J, Peters HP, Rijken PF, van den Hoogen FJ, de Wilde PC, van der Kogel AJ: Patterns of proliferation related to vasculature in human head-and-neck carcinomas before and after transplantation in nude mice. Int J Radiat Oncol Biol Phys. 2001, 51: 1346-10.1016/S0360-3016(01)02605-0.View ArticlePubMedGoogle Scholar
- Ljungkvist AS, Bussink J, Rijken PF, Kaanders JH, van der Kogel AJ, Denekamp J: Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2002, 54: 215-228.View ArticlePubMedGoogle Scholar
- Bussink J, van Herpen CM, Kaanders JH, Oyen WJ: PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol. 2010, 11: 661-669. 10.1016/S1470-2045(09)70353-5.View ArticlePubMedGoogle Scholar
- Yaromina A, Krause M, Baumann M: Individualization of cancer treatment from radiotherapy perspective. Mol Oncol. 2012, 6: 211-221. 10.1016/j.molonc.2012.01.007.View ArticlePubMedGoogle Scholar
- Bussink J, Kaanders JH, van der Graaf WT, Oyen WJ: PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol. 2011, 8: 233-242. 10.1038/nrclinonc.2010.218.View ArticlePubMedGoogle Scholar
- Buerkle A, Weber WA: Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev. 2008, 27: 545-554. 10.1007/s10555-008-9151-x.View ArticlePubMedGoogle Scholar
- Arens AI, Troost EG, Schinagl D, Kaanders JH, Oyen WJ: FDG-PET/CT in radiation treatment planning of head and neck squamous cell carcinoma. Q J Nucl Med Mol Imaging. 2011, 55: 521-528.PubMedGoogle Scholar
- Rademakers SE, Span PN, Kaanders JH, Sweep FC, van der Kogel AJ, Bussink J: Molecular aspects of tumour hypoxia. Mol Oncol. 2008, 2: 41-53. 10.1016/j.molonc.2008.03.006.View ArticlePubMedGoogle Scholar
- Stegeman H, Rademakers SE, Span PN, Takes RP, van der Kogel A, Kaanders JHAM, Bussink J: Hypoxia, metabolism, and growth factor signaling in head and neck squamous cell carcinoma: Correlation between primary and xenograft tumors. Head Neck. 2013, 1-2. Epub ahead of print Nov 2013Google Scholar
- Nijkamp MM, Span PN, Hoogsteen IJ, van der Kogel AJ, Kaanders JH, Bussink J: Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol. 2011, 99: 344-348. 10.1016/j.radonc.2011.05.066.View ArticlePubMedGoogle Scholar
- Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH: Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer. 2011, 11: 167-10.1186/1471-2407-11-167.View ArticlePubMedPubMed CentralGoogle Scholar
- Rangan SR: A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer. 1972, 29: 117-121. 10.1002/1097-0142(197201)29:1<117::AID-CNCR2820290119>3.0.CO;2-R.View ArticlePubMedGoogle Scholar
- Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, Ferris RL, Lai SY: Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck. 2007, 29: 163-188. 10.1002/hed.20478.View ArticlePubMedGoogle Scholar
- Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA: Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006, 47: 999-1006.PubMedGoogle Scholar
- Visser EP, Disselhorst JA, Brom M, Laverman P, Gotthardt M, Oyen WJ, Boerman OC: Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med. 2009, 50: 139-147.View ArticlePubMedGoogle Scholar
- Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Versleijen-Jonkers YM, Oyen WJ, van der Graaf WT, Boerman OC: ImmunoSPECT and immunoPET imaging of IGF-1R expression with radiolabeled R1507 in a triple negative breast cancer model. J Nucl Med. 2010, 51: 1565-1572. 10.2967/jnumed.110.075648.View ArticlePubMedGoogle Scholar
- Schinagl DA, Vogel WV, Hoffmann AL, van Dalen JA, Oyen WJ, Kaanders JH: Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007, 69: 1282-1289. 10.1016/j.ijrobp.2007.07.2333.View ArticlePubMedGoogle Scholar
- Hoeben BA, Molkenboer-Kuenen JD, Oyen WJ, Peeters WJ, Kaanders JH, Bussink J, Boerman OC: Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. Int J Cancer. 2011, 129: 870-878. 10.1002/ijc.25727.View ArticlePubMedGoogle Scholar
- Rijken PF, Bernsen HJ, Peters JP, Hodgkiss RJ, Raleigh JA, van der Kogel AJ: Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys. 2000, 48: 571-582. 10.1016/S0360-3016(00)00686-6.View ArticlePubMedGoogle Scholar
- Bachtiary B, Boutros PC, Pintilie M, Shi W, Bastianutto C, Li JH, Schwock J, Zhang W, Penn LZ, Jurisica I, Fyles A, Liu FF: Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res. 2006, 12: 5632-5640. 10.1158/1078-0432.CCR-06-0357.View ArticlePubMedGoogle Scholar
- Breiman L: Random Forests. Machine Learning. 2001, 45: 5-32. 10.1023/A:1010933404324.View ArticleGoogle Scholar
- Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J: Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging. 2008, 35: 2294-2303. 10.1007/s00259-008-0888-9.View ArticlePubMedGoogle Scholar
- Yamada T, Uchida M, Kwang-Lee K, Kitamura N, Yoshimura T, Sasabe E, Yamamoto T: Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. Oral Surg Oral Med, Oral Pathol Oral Radiol. 2012, 113: 464-471. 10.1016/j.tripleo.2011.04.006.View ArticleGoogle Scholar
- Minn H, Clavo AC, Grenman R, Wahl RL: In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 1995, 36: 252-258.PubMedGoogle Scholar
- Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD, Jones DR: Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg. 2009, 35: 699-705. 10.1016/j.ejcts.2008.11.029.View ArticlePubMedPubMed CentralGoogle Scholar
- Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M: [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009, 27: 2697-2704. 10.1200/JCO.2008.18.8383.View ArticlePubMedPubMed CentralGoogle Scholar
- Aubry K, Paraf F, Monteil J, Bessede JP, Rigaud M: Characterization of a new rat model of head and neck squamous cell carcinoma. In Vivo. 2008, 22: 403-408.PubMedGoogle Scholar
- Lee EJ, Kim J, Lee SA, Kim EJ, Chun YC, Ryu MH, Yook JI: Characterization of newly established oral cancer cell lines derived from six squamous cell carcinoma and two mucoepidermoid carcinoma cells. Exp Mol Med. 2005, 37: 379-390. 10.1038/emm.2005.48.View ArticlePubMedGoogle Scholar
- Schinagl DA, Span PN, Oyen WJ, Kaanders JH: Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging. 2011, 38: 1449-1458. 10.1007/s00259-011-1789-x.View ArticlePubMedPubMed CentralGoogle Scholar
- van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, Rupa D, Pastorekova S, Stroobants S, Buell U, Lambin P, Vansteenkiste J, De Ruysscher D: The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007, 43: 1392-1398. 10.1016/j.ejca.2007.03.027.View ArticlePubMedGoogle Scholar
- Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN, Hetzel M: Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003, 44: 1426-1431.PubMedGoogle Scholar
- Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, Zegers CM, Gillies R, Boellard R, Dekker A, Aerts HJ: Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012, 48: 441-446. 10.1016/j.ejca.2011.11.036.View ArticlePubMedPubMed CentralGoogle Scholar
- Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, Forster K, Aerts HJ, Dekker A, Fenstermacher D, Goldgof DB, Hall LO, Lambin P, Balagurunathan Y, Gatenby RA, Gillies RJ: Radiomics: the process and the challenges. Magn Reson Imaging. 2012, 30: 1234-1248. 10.1016/j.mri.2012.06.010.View ArticlePubMedPubMed CentralGoogle Scholar
- Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, Corcos L, Visvikis D: Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011, 52: 369-378. 10.2967/jnumed.110.082404.View ArticlePubMedPubMed CentralGoogle Scholar
- Yu H, Caldwell C, Mah K, Mozeg D: Coregistered FDG PET/CT-based textural characterization of head and neck cancer for radiation treatment planning. IEEE Trans Med Imag. 2009, 28: 374-383.View ArticleGoogle Scholar
- Haralick RM, Shanmugan K, Dinstein I: Textural Features for Image Classification. IEEE Trans Syst Man Cybern. 1973, 3: 610-621.View ArticleGoogle Scholar
- Stoecker WV, Wronkiewiecz M, Chowdhury R, Stanley RJ, Xu J, Bangert A, Shrestha B, Calcara DA, Rabinovitz HS, Oliviero M, Ahmed F, Perry LA, Drugge R: Detection of granularity in dermoscopy images of malignant melanoma using color and texture features. Comput Med Imaging Graph. 2011, 35: 144-147. 10.1016/j.compmedimag.2010.09.005.View ArticlePubMedGoogle Scholar
- Boland MV, Murphy RF: A neural network classifier capable of recognizing the patterns of all major subcellular structures in fluorescence microscope images of HeLa cells. Bioinformatics. 2001, 17: 1213-1223. 10.1093/bioinformatics/17.12.1213.View ArticlePubMedGoogle Scholar
- Shamir L, Wolkow CA, Goldberg IG: Quantitative measurement of aging using image texture entropy. Bioinformatics. 2009, 25: 3060-3063. 10.1093/bioinformatics/btp571.View ArticlePubMedPubMed CentralGoogle Scholar
- Goethals L, Perneel C, Debucquoy A, De Schutter H, Borghys D, Ectors N, Geboes K, McBride WH, Haustermans KM: A new approach to the validation of tissue microarrays. J Pathol. 2006, 208: 607-614. 10.1002/path.1934.View ArticlePubMedGoogle Scholar
- Bussink J, Kaanders JH, Rijken PF, Peters JP, Hodgkiss RJ, Marres HA, van der Kogel AJ: Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide. Radiother Oncol. 1999, 50: 173-184. 10.1016/S0167-8140(99)00010-9.View ArticlePubMedGoogle Scholar
- Bussink J, Kaanders JH, van der Kogel AJ: Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy. Radiother Oncol. 2007, 82: 10-17. 10.1016/j.radonc.2006.10.022.View ArticlePubMedGoogle Scholar
- Hoeben BAW, Bussink J, Troost EGC, Oyen WJG, Kaanders JHAM: Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. Acta Oncol. 2013, 52: 1257-1271. 10.3109/0284186X.2013.812799.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/130/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.